This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

PET-CT and Circulating Tumor Cells in Colorectal Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
CCTU, Chinese University of Hong Kong
ClinicalTrials.gov Identifier:
NCT01163305
First received: June 24, 2010
Last updated: May 3, 2017
Last verified: April 2017
History of Changes
June 24, 2010
May 3, 2017
June 30, 2010
April 27, 2017   (Final data collection date for primary outcome measure)
Tumor metabolic response via FDG-PET at 4 weeks after chemotherapy [ Time Frame: 2 years ]
  • Tumor metabolic response via FDG-PET at 4 weeks after chemotherapy [ Time Frame: 2 years ]
  • Circulating tumor cells level changes at 4 weeks after chemotherapy [ Time Frame: 2 years ]
  • RECIST-based tumor response at 10 weeks after chemotherapy [ Time Frame: 2 years ]
Complete list of historical versions of study NCT01163305 on ClinicalTrials.gov Archive Site
  • Overall survival [ Time Frame: 4 years ]
  • Progression-free survival [ Time Frame: 4 years ]
  • serum carcinoembryonic antigen (CEA) level [ Time Frame: 4 years ]
  • Circulating tumor cells level changes at 4 weeks after chemotherapy [ Time Frame: 2 years ]
  • RECIST-based tumor response at 10 weeks after chemotherapy [ Time Frame: 2 years ]
  • Overall survival [ Time Frame: 4 years ]
  • Progression-free survival [ Time Frame: 4 years ]
  • serum carcinoembryonic antigen (CEA) level [ Time Frame: 4 years ]
Not Provided
Not Provided
 
PET-CT and Circulating Tumor Cells in Colorectal Cancer
Identifying an Early Indicator of Drug Efficacy in Patients With Advanced Colorectal Cancer - a Prospective Evaluation of Circulating Tumor Cells, Positron-emission Tomography Scan and RECIST Criteria
The purpose of this study is to identify an early indicator of drug efficacy in patients with advanced colorectal cancer - a prospective evaluation of circulating tumor cells, positron-emission tomography scan and RECIST criteria.
  1. To determine if measuring both tumor metabolic response (via FDG-PET scan) & circulating tumor cells (CirTC) at 4 weeks after starting treatment, is a better predictor of clinical outcome than measuring either modality alone in patients with metastatic colorectal cancer (CRC) who are undergoing first-line oxaliplatin-based chemotherapy.
  2. To determine if a new method of assessing drug response (measuring tumor metabolic response via FDG-PET & CirTC at 4 weeks after starting treatment) better predicts clinical outcome than the conventional method (measuring radiological changes in tumor dimensions at 10 weeks after starting treatment via the 'Response Evaluation Criteria in Solid Tumors' - RECIST).
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
circulating tumor cells
Probability Sample
patients with metastatic colorectal cancer
  • Colorectal Cancer
  • Metastasis
Drug: Chemotherapy
The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy
metastatic colorectal cancer
Intervention: Drug: Chemotherapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
84
April 27, 2017
April 27, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Metastatic colorectal cancer patients not received prior drug treatment for metastatic CRC
  • Age >= 18 years
  • (ECOG) performance status of 0-2
  • Measurable tumor sites by RECIST criteria
  • Adequate bone marrow, renal & hepatic functions

Exclusion Criteria:

  • Patients with diabetes mellitus
  • presence of hyperglycemia
  • Pregnant or lactating patients
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Hong Kong
 
 
NCT01163305
COL016
No
Not Provided
Not Provided
Not Provided
CCTU, Chinese University of Hong Kong
Chinese University of Hong Kong
Not Provided
Principal Investigator: Brigette Ma, MD, FRCP Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong
Chinese University of Hong Kong
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP